The role of statistics in the design and analysis of companion diagnostic (CDx) studies

Companion diagnostic tests are crucial in the development of precision medicine. These tests provide information that is essential for the safe and effective use of specific therapeutic products. Statistics plays a key role in the design and analysis of studies to demonstrate the safety and effectiveness of the companion diagnostics. This article can serve as an introduction to companion diagnostics for therapeutic statisticians and for diagnostic ones as well as a discussion of some of the statistical challenges. The topics include biomarker development, diagnostic performance, misclassification, prospective-retrospective validation, bridging studies, missing data, follow-on diagnostics and complex signatures.

[1]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[2]  Tinghui Yu,et al.  The impact of companion diagnostic device measurement performance on clinical validation of personalized medicine , 2015, Statistics in medicine.

[3]  R. Simon.  Stratification and Partial Ascertainment of Biomarker Value in Biomarker-Driven Clinical Trials , 2014, Journal of biopharmaceutical statistics.

[4]  L. V. van't Veer,et al.  Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. , 2006, Journal of the National Cancer Institute.

[5]  Statistical evaluation of drug efficacy for bridging study in companion diagnostic test trials , 2016, Journal of biopharmaceutical statistics.

[6]  Stephen J. Ruberg,et al.  Personalized Medicine: Four Perspectives of Tailored Medicine , 2015 .

[7]  Giovanni Parmigiani,et al.  Adaptive Randomization of Neratinib in Early Breast Cancer. , 2016, The New England journal of medicine.

[8]  J. Samet,et al.  Food and Drug Administration , 2007, BMJ : British Medical Journal.

[9]  Meijuan Li.  Statistical Consideration and Challenges in Bridging Study of Personalized Medicine , 2015, Journal of biopharmaceutical statistics.

[10]  A bivariate Bayesian framework for simultaneous evaluation of two candidate companion diagnostic assays in a new drug clinical trial , 2021, Biostatistics & Epidemiology.

[11]  Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests ; Draft Guidance for Industry and FDA Reviewers Draft Guidance-Not for Implementation , 2003 .

[12]  D. Rennie,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative , 2003, BMJ : British Medical Journal.

[13]  Daniel J Sargent,et al.  Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Pennello,et al.  Clinical Trial Designs to Evaluate Predictive Biomarkers: What’s Being Estimated? , 2016, Springer Proceedings in Mathematics & Statistics.

[15]  Elizabeth Mansfield,et al.  Companion diagnostics. , 2010, Clinical advances in hematology & oncology : H&O.

[16]  Maqc Consortium.  The MicroArray Quality Control ( MAQC )-II study of common practices for the development and validation of microarray-based predictive models , 2012 .

[17]  Gregory Campbell,et al.  Missing Data in the Regulation of Medical Devices , 2011, Journal of biopharmaceutical statistics.

[18]  Richard Pazdur,et al.  An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies , 2016, Clinical Cancer Research.

[19]  E. Frenkel,et al.  Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays , 2000, Journal of clinical pathology.

[20]  Kristian Linnet,et al.  Partly nonparametric approach for determining the limit of detection. , 2004, Clinical chemistry.

[21]  John M S Bartlett,et al.  HER2 testing: current status and future directions. , 2014, Cancer treatment reviews.

[22]  Jonathan Denne,et al.  Identifying a Subpopulation for a Tailored Therapy: Bridging Clinical Efficacy From a Laboratory-Developed Assay to a Validated In Vitro Diagnostic Test Kit , 2014 .

[23]  M. Schlumpberger,et al.  Liquid Biopsy Preservation Solutions for Standardized Pre-Analytical Workflows—Venous Whole Blood and Plasma , 2018, Current Pathobiology Reports.

[24]  Kevin C. Dorff,et al.  The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models , 2010, Nature Biotechnology.

[25]  Gene A Pennello,et al.  Analytical and clinical evaluation of biomarkers assays: When are biomarkers ready for prime time? , 2013, Clinical trials.

[26]  Xu Yan,et al.  Missing Data Handling Methods in Medical Device Clinical Trials , 2009, Journal of biopharmaceutical statistics.

[27]  Meijuan Li.  Statistical Methods for Clinical Validation of Follow-On Companion Diagnostic Devices via an External Concordance Study , 2016 .